2017

Engineering of GlcNAc-1-phosphotransferase for production of highly phosphorylated lysosomal enzymes for enzyme replacement therapy

Lin Liu
Washington University School of Medicine in St. Louis

Wang-Sik Lee
Washington University School of Medicine in St. Louis

Balraj Doray
Washington University School of Medicine in St. Louis

Stuart Kornfeld
Washington University School of Medicine in St. Louis

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
http://digitalcommons.wustl.edu/open_access_pubs/5887

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Engineering of GlcNAc-1-Phosphotransferase for Production of Highly Phosphorylated Lysosomal Enzymes for Enzyme Replacement Therapy

Lin Liu,1 Wang-Sik Lee,1 Balraj Doray,1 and Stuart Kornfeld1

Several lysosomal enzymes currently used for enzyme replacement therapy in patients with lysosomal storage diseases contain very low levels of mannose 6-phosphate, limiting their uptake via mannose 6-phosphate receptors on the surface of the deficient cells. These enzymes are produced at high levels by mammalian cells and depend on endogenous GlcNAc-1-phosphotransferase α/β precursor to phosphorylate the mannose residues on their glycan chains. We show that co-expression of an engineered truncated GlcNAc-1-phosphotransferase α/β precursor and the lysosomal enzyme of interest in the producing cells resulted in markedly increased phosphorylation and cellular uptake of the secreted lysosomal enzyme. This method also results in the production of highly phosphorylated acid β-glucocerebrosidase, a lysosomal enzyme that normally has just trace amounts of this modification.

INTRODUCTION

Enzyme replacement therapy (ERT) is currently the major form of treatment for a number of lysosomal storage diseases, although its efficacy varies among the individual disorders.1 Most of these inherited disorders arise from the lack of activity of a single lysosomal enzyme, which leads to the accumulation of the material normally degraded by the enzyme. The build-up of the storage material in the lysosome eventually results in cell and organ dysfunction. The goal of ERT is to introduce sufficient amounts of normal enzyme into the lysosomes of the deficient cells to clear the storage material and restore lysosome function. This form of therapy was first used in patients with type 1 Gaucher disease, who lack acid β-glucocerebrosidase (GBA) activity and accumulate glucosylceramide primarily in macrophage type cells.2 The replacement enzyme, containing N-linked glycans with terminal mannose residues, is infused intravenously and taken up by macrophages via cell surface mannose receptors. The endocytosed enzyme is then transported via endosomes to lysosomes, where it functions with good clinical results in this disorder.3

Because most cell types lack mannose receptors, the replacement enzymes used to treat lysosomal storage disorders that involve cell types other than macrophages use binding to the cation-independent mannose 6-phosphate receptor (CI-MPR) at the cell surface for subsequent delivery to lysosomes. In this regard, studies of a mouse model of Gaucher disease have produced evidence for the involvement of multiple cell lineages other than macrophages in the pathophysiology of this disorder, particularly osteoblasts, dendritic cells, and T cells.4 Therefore, a therapy that included these cell types may be of clinical benefit in this disorder.

The enzymes used for ERT are purified from the secretions of mammalian cells, mostly Chinese hamster ovary cells, engineered to produce high levels of the enzyme of interest. The feasibility of this approach is dependent upon the ability of the endogenous GlcNAc-1-phosphotransferase to phosphorylate mannose residues of the N-glycans of the expressed lysosomal enzyme. Some of the replacement enzymes produced by this technique are highly phosphorylated and bind well to the CI-MPR. Others, however, are poorly phosphorylated, limiting their effectiveness in ERT. This includes the Pompe disease enzyme (acid α-glucosidase [GAA]) and the alpha-mannosidosis enzyme (lysosomal acid α-mannosidase [LAMAN]).5,6 In addition, the GBA currently used in the treatment of Gaucher disease contains a very low level of Man-6-P.7

We considered two possibilities for why GAA and LAMAN are poorly phosphorylated. First, the activity of the endogenous GlcNAc-1-phosphotransferase in the producing cells may be insufficient to effectively phosphorylate the high levels of these enzymes being synthesized. If this were the case, co-transfection of GlcNAc-1-phosphotransferase with the lysosomal enzyme would be expected to enhance phosphorylation. One potential limitation to this approach is that overexpression of wild-type (WT) GlcNAc-1-phosphotransferase with the lysosomal enzyme would be expected to enhance phosphorylation. A second possibility is that these two lysosomal enzymes are poor substrates for WT GlcNAc-1-phosphotransferase compared with other lysosomal enzymes. Evidence that this is the case with GAA has been presented.5 GBA differs from the other...
lysosomal enzymes in that it is known to be transported to lysosomes by a Man-6-P-independent pathway. This fact, plus its very low content of Man-6-P, has led to the conclusion that it is not a substrate for GlcNac-1-phosphotransferase.

During the course of studies to understand the roles of the various domains of the α/β subunits of GlcNac-1-phosphotransferase, we engineered a modified enzyme that bypasses the requirement for proteolytic cleavage, is highly expressed and has good activity toward a panel of endogenous lysosomal enzymes. We then compared the ability of the WT and modified GlcNac-1-phosphotransferase to act on a number of poorly phosphorylated lysosomal enzymes when co-transfected into cells. Our findings document that it is possible to substantially enhance the phosphorylation of lysosomal enzymes, including GBA, that are poor substrates for GlcNac-1-phosphotransferase using our modified GlcNac-1-phosphotransferase. Acid hydrolases synthesized by this procedure display increased binding to Man-6-P receptors and enhanced uptake by target cells compared to the enzymes produced by the current procedure.

**RESULTS**

**Generation of a Highly Active Variant of GlcNac-1-Phosphotransferase**

GlcNac-1-phosphotransferase is an α2β2γ2 hexamer encoded by two genes (GNPTAB and GNPTG). We have reported that the α/β subunits are able to phosphorylate most lysosomal enzymes in the absence of γ. Therefore, we used a construct encoding only the α/β precursor as the starting source of mannose phosphorylating activity. Proteolytic cleavage of this precursor at K928 to give rise to the α and β subunits is mediated by the Site-1 protease in the Golgi, and this process is essential for catalytic competency of the protein. The α subunit contains two Notch modules and a DNA methyltransferase-associated protein (DMAP) interaction domain that mediate recognition. In S1-D and S1-S3, the 236 aa human spacer-1 (S1) sequence was replaced with 29 aa of the D. discoides sequence, in addition to removal of N1 through most of spacer-3 (S3) up to the K928 cleavage site (asterisk). We have reported that the α/β precursor and the deletion mutants expressed in GNPTAB−/− HeLa cells. The indicated amount of each cell extract was loaded, and the α/β precursor and β subunits were detected with an anti-V5 antibody. (C) Catalytic activity of WT α/β precursor and the deletion mutants toward αMM using equal amounts of whole-cell extracts. The vector-only transfected GNPTAB−/− HeLa cell extract served as a control, and WT value was set to 100% after subtraction of vector-only background. (D and E) Transfection of GNPTAB−/− HeLa cells with either WT α/β precursor or the various deletion mutant cDNAs. The degree of phosphorylation mediated WT or mutant proteins was determined by binding of three endogenous lysosomal enzymes to CI-MPR-affinity beads. Bound material was assayed for activity, and values obtained with cells transfected with WT α/β are set to 100%. (F) Mannose phosphorylation of total soluble proteins was determined by transfecting GNPTAB−/− HeLa cells with WT α/β precursor or the indicated deletion mutant cDNAs, followed by [2-3H]-mannose labeling. Values shown are calculated as the percentage of counts recovered with the CI-MPR affinity beads as a fraction of the total counts in the phosphotungstic acid precipitate. The background value of 0.8 ± 0.3% was subtracted to yield the final depicted values. *p < 0.05, **p < 0.01. (G) Immunoblot analysis of GNA TAb−/− HeLa cells co-transfected with the expression plasmids along with empty vector, WT α/β precursor, or the indicated deletion mutant cDNAs. Cell lysates were incubated with CI-MPR-affinity beads, and the binding of the various proteins was determined by probing the blots with the following antibodies: anti-HA for Renin, anti-myc for PoFut2, anti-Strep tag for the vWF A1A2A3 domains, and antibodies generated against the native protein for GP, Lamp1, and Lamp2. Error bars represent mean ± SD.
spacer-2 contains the γ-subunit binding site.\textsuperscript{2,14} Besides these domains, the α and β subunits also harbor four Stealth domains that together form the catalytic core of the protein. The Stealth domains of all eukaryotic GlcNAc-1-phosphotransferases are highly conserved and resemble sequences within bacterial proteins that encode sugar-phosphate transferases involved in cell wall polysaccharide biosynthesis.\textsuperscript{15} In contrast to the mammalian enzymes, however, the bacterial proteins such as the \textit{N. meningitidis} GlcNAc-1-phosphotransferase (Figure S1) lack the other domains, with no evidence that proteolytic cleavage is necessary for catalytic activation.\textsuperscript{16} Thus, we asked if it was possible to engineer a human GlcNAc-1-phosphotransferase that is not cleaved but retained high catalytic activity toward the N-linked glycans of lysosomal enzymes.

We have previously reported that a construct (N1-D; Figure 1A) lacking the region from the Notch1 module to the end of DMAP (residues 438–819) is well expressed and has good catalytic activity toward the simple sugar α-methylmannoside (zMM) but is unable to phosphorylate lysosomal enzymes.\textsuperscript{12} When deletion of this region was combined with removal of spacer-1 (construct S1-D), the expressed protein (Figure 1B, lane 5) had similar activity as N1-D toward zMM but slightly greater phosphorylation activity toward the lysosomal enzyme panel (Figures 1C and 1D), despite only a small amount of the β subunit product resulting from this construct (Figure 1B, compare lanes 4 and 5). This is in agreement with our recent study that upon removal of spacer-1, the uncleaved α/β precursor retains some catalytic activity.\textsuperscript{13} To determine if it was possible to bypass the requirement for cleavage altogether, construct N1-S3 was made, which extended the deletion from Notch1 up to the Site-1 protease cleavage site in spacer-3 (residues 438–928). This construct, which remained a single-chain molecule, was very highly expressed (Figure 1B, lane 6), properly localized to the Golgi (Figure S2), and was 17-fold more active toward zMM than observed with WT α/β (Figure 1C). However, it only phosphorylated the panel of lysosomal enzymes about 30%–40% as well as the WT transferase.\textsuperscript{12} It also phosphorylated the lysosomal enzyme panel better than observed with N1-S3, ranging from 56%–117% of WT level (Figure 1E). Strikingly, we noted that S1-S3 phosphorylated the total pool of cellular soluble glycoproteins 3-fold greater than N1-S3 and the WT enzyme, consistent with increased phosphorylation of lysosomal enzymes that are poorly phosphorylated by the WT enzyme as well as an enhanced ability to phosphorylate non-lysosomal glycoproteins (Figure 1F). To test the latter possibility, we determined the ability of the various constructs to phosphorylate a panel of non-lysosomal glycoproteins, two of which were known to be weak substrates of WT GlcNAc-1-phosphotransferase, namely, Renin and protein O-fucosyltransferase 2 (PoFut2).\textsuperscript{17,18} Phosphorylation was determined by binding to CI-MPR beads following by western blotting to detect the proteins. As shown in Figure 1G, the S1-S3 construct phosphorylated Renin, PoFut2, glycopepsinogen (GP), and the von Willebrand factor (vWF) A1A2A3 domain, whereas the WT construct only phosphorylated Renin weakly in this assay. The N1-S3 construct acted on these proteins as well but to a lesser degree than S1-S3. None of these constructs phosphorylated the membrane glycoproteins, Lamp1 and Lamp2.

In an attempt to further reduce human GlcNAc-1-phosphotransferase to resemble the \textit{N. meningitidis} enzyme (Figure S1), a series of deletions within spacer-4 were generated. However, none of these mutants displayed enzyme activity toward zMM (data not shown).

\textbf{Co-transfection of GlcNAc-1-Phosphotransferase with Lysosomal Enzymes Enhances Phosphorylation}

On the basis of the above findings, we selected construct S1-S3 along with the WT α/β precursor construct to co-transfect with plasmids encoding the three poorly phosphorylated lysosomal enzymes (LAMAN, GAA, and GBA) and GLA as a control for a well-phosphorylated enzyme. In the initial experiment, the constructs were co-expressed in \textit{GNPTAB}−/− HeLa cells, followed by incubation with [2-\textsuperscript{3}H]mannose to label the N-linked glycans of the lysosomal enzymes. The media was collected and the secreted proteins were immunoprecipitated and analyzed for their content of glycans containing one or two Man-6-P residues. As shown in Figure 2, the S1-S3 construct produced 2.1- to 4.9-fold greater phosphorylation of the glycans present on the panel of lysosomal enzymes that were co-expressed with this truncated α/β precursor relative to WT.

Next we co-transfected either Expi293 cells or mouse D9 L cells (lacking the CI-MPR) with the same plasmids and collected the media after 48–72 hr to use as a source of secreted lysosomal enzymes for receptor binding and cell uptake experiments. As a control for phosphorylation mediated by the endogenous GlcNAc-1-phosphotransferase, cells were transfected with plasmids encoding the lysosomal enzymes but not with the cDNAs for the α/β precursors. A representative Coomassie blue-stained SDS gel of the media from Expi293 cells is shown in Figure S3. In all instances, the enzyme secreted by cells co-transfected with the S1-S3 construct bound to the CI-MPR-beads to a much greater extent than observed with the lysosomal enzymes.
expressed alone in the cells (Figure 3). This is indicative of enhanced phosphorylation. Further, with the exception of LAMAN, co-transfection with S1-S3 resulted in significantly greater lysosomal enzyme binding to the CI-MPR-beads than obtained with the WT enzyme. The impact of the increased Man-6-P content of the various lysosomal enzymes on their uptake by HeLa cells is shown in Table 1. In all four instances, the enzymes secreted by cells co-transfected with the plasmid encoding the truncated α/β precursor were internalized many fold better than enzyme secreted by cells using only the endogenous GlcNAc-1-phosphotransferase. Similar results were obtained with co-transfection of the WT α/β precursor with the exception of GAA, consistent the CI-MPR-bead binding results. Most of the uptake was blocked by the presence of 5 mM Man-6-P in the media, showing that the uptake is mediated by the CI-MPR. The results with LAMAN were particularly striking, with Man-6-P-inhibitable uptake being stimulated by 130- to 153-fold. It is also notable that the GBA was internalized to a great extent in a Man-6-P-dependent manner.

DISCUSSION

The findings presented here establish that phosphorylation of expressed lysosomal enzymes can be substantially increased by co-transfection with an engineered truncated α/β precursor of GlcNAc-1-phosphotransferase and, in some instances, with the WT α/β precursor. Importantly, the γ subunit, encoded by a different gene, is not required for this effect. This simplifies construction of the producing cells. The enhanced phosphorylation of the lysosomal enzymes increases their binding to the CI-MPR and uptake by cells.

This effect even occurs with lysosomal enzymes such as GLA that are well phosphorylated by the endogenous GlcNAc-1-phosphotransferase. But most important is the finding that this method enhances the phosphorylation and uptake of human LAMAN and GAA, two lysosomal enzymes that are poorly phosphorylated by endogenous GlcNAc-1-phosphotransferase. In addition, the production of GBA containing high levels of Man-6-P offers the opportunity to restore enzyme activity to cell types in patients with Gaucher disease who lack the mannose receptor. This is of particular interest in light of the reported findings in a mouse model of Gaucher disease that cell types other than macrophages are dysfunctional in this disorder.4 The availability of highly phosphorylated GBA could potentially provide additional benefit to the current therapy that is targeted specifically to macrophages.

In conclusion, the methods described here have the potential to significantly improve the effectiveness of lysosomal enzymes in ERT. In addition to providing better cell uptake, these preparations may allow lower doses to be administered to patients, perhaps at less frequent intervals. The method should be applicable to the production of phosphorylated lysosomal enzymes for other lysosomal storage diseases that may be amenable to ERT.

MATERIALS AND METHODS

Cell Lines

Expi293 cells (Life Technologies) were grown in suspension in Expi293 expression medium (Life Technologies). The GNPTAB−/−
HeLa cell line has been described in detail elsewhere. HeLa cells were maintained as a monolayer in DMEM (Life Technologies) containing 0.11 g/L sodium pyruvate and 4.5 g/L glucose, supplemented with 10% (vol/vol) fetal bovine serum (FBS) (Atlanta Biologicals), 100,000 U/L penicillin, 100 mg/L streptomycin (Life Technologies), and 2 mM L-glutamine (Life Technologies). The CI-MPR negative mouse D9 L-cell line has been described. D9 L-cells were maintained as a monolayer in α-MEM (Life Technologies) containing 100,000 U/L penicillin and 100 mg/L streptomycin (Life Technologies).

**DNA Constructs**

Human GNPTAB-V5/His 8 in pcDNA6 and the N1-D deletion construct has been described. Constructs S1-D and S1-S3 were generated in two steps as follows: in the first step, the human spacer-1 sequence was replaced with *D. discoideum* spacer-1 using a 0.5 kb gBlocks gene fragment (IDT) in a two-stage overlap extension PCR (OE-PCR). Nucleotides corresponding to amino acids 438–819 or 438–928 were subsequently removed in the second step to generate S1-D and S1-S3, respectively. The construct N1-S3 was generated by deleting nucleotides encoding amino acids 438–928 from the WT construct. The LAMAN-myc-Flag cDNA was purchased from Origene, while the GAA cDNA was a kind gift of Eline van Meel (Leiden University). The GLA and GBA cDNAs were generously provided by Amicus Therapeutics. A C-terminal myc-tag was appended to the GBA and GAA c-DNA. The PoFut2-myc cDNA was a gift from Robert Haltiwanger (University of Georgia, Athens, GA). Renin-HA cDNA was purchased from Addgene (Cambridge, MA), while the plasmid, vWF-A1A2A3-Strep-pCDNA6, was kindly provided by Joshua Muia and J. Evan Sadler (Washington University School of Medicine, St. Louis, MO).

**Phosphotransferase Assay**

Constructs encoding the WT and S1-S3 α/β precursors were expressed in GNPTAB−/− HeLa by transfection with Lipofectamine 3000 (Life Technologies) according to the manufacturer’s protocol.

---

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>PTase</th>
<th>Total Units Added</th>
<th>Man-6-P</th>
<th>% Uptake*</th>
<th>M6PR Dependent</th>
<th>Fold Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>endogenous</td>
<td>670</td>
<td>-</td>
<td>0.76 ± 0.23</td>
<td>0.14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAMAN</td>
<td>WTα/β</td>
<td>359</td>
<td>+</td>
<td>24.70 ± 1.34</td>
<td>21.5</td>
<td>153</td>
</tr>
<tr>
<td>S1-S3</td>
<td>530</td>
<td>+</td>
<td>22.46 ± 4.07</td>
<td>18.2</td>
<td>130</td>
<td></td>
</tr>
<tr>
<td>endogenous</td>
<td>5.7</td>
<td>-</td>
<td>4.05 ± 0.46</td>
<td>3.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAA</td>
<td>WTα/β</td>
<td>3.8</td>
<td>+</td>
<td>3.31 ± 1.13</td>
<td>2.9</td>
<td>0.8</td>
</tr>
<tr>
<td>S1-S3</td>
<td>3.2</td>
<td>+</td>
<td>1.27 ± 0.90</td>
<td>9.8</td>
<td>2.6</td>
<td></td>
</tr>
<tr>
<td>endogenous</td>
<td>2.7</td>
<td>-</td>
<td>10.74 ± 1.94</td>
<td>5.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GBA</td>
<td>WTα/β</td>
<td>2.3</td>
<td>+</td>
<td>46.73 ± 4.00</td>
<td>37.4</td>
<td>7.3</td>
</tr>
<tr>
<td>S1-S3</td>
<td>2.8</td>
<td>+</td>
<td>49.74 ± 11.53</td>
<td>41.1</td>
<td>8.0</td>
<td></td>
</tr>
<tr>
<td>endogenous</td>
<td>194</td>
<td>-</td>
<td>4.67 ± 1.26</td>
<td>0.11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLA</td>
<td>WTα/β</td>
<td>141</td>
<td>+</td>
<td>2.72 ± 0.91</td>
<td>1.7</td>
<td></td>
</tr>
<tr>
<td>S1-S3</td>
<td>237</td>
<td>+</td>
<td>7.01 ± 0.69</td>
<td>6.1</td>
<td>3.5</td>
<td></td>
</tr>
</tbody>
</table>

One unit = 1 nmol 4-methylumbelliferone released per hour. Uptake experiments were performed in either the absence or the presence of 5 mM Man-6-P.

*Percentage uptake per 200 μg cell protein in 24 hr.
Fifty-eight hours post-transfection, cells in six-well plates were harvested and lysed in 250 μL of buffer A (25 mM Tris-Cl [pH 7.2], 150 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail). Either 10 μL (WT) or 2 μL (S1-S3) of cell extract was incubated in buffer B (50 mM Tris-Cl [pH 7.4], 10 mM MgCl₂, 10 mM MnCl₂, 2 mg/mL BSA, 2 mM ATP) in the presence of 75 μM UDP-GlcNAc, 1 μCi UDP-[3H]GlcNAc, and 100 mM α-MM in a final volume of 50 μL for 1 hr at 37°C. The reactions were stopped by the addition of 1 mL of 2 mM EDTA [pH 8.0], and the samples were subjected to QAE-Sephadex chromatography as previously described.11

**Western Blotting**
Proteins resolved by SDS-PAGE under reducing conditions were transferred to nitrocellulose membrane and detected with antibodies as described in the figure legends. The indicated amounts of whole-cell extracts were loaded on the gels.

**Immunofluorescence Microscopy**
To visualize the subcellular localization of WT α/β and the S1-S3 mutant, the constructs were transfected into GNPTAB−/− HeLa cells using Lipofectamine 3000 according to the manufacturer’s protocol. Twenty-four hours post-transfection, the cells were fixed with 4% formaldehyde (Sigma-Aldrich) and the α/β subunits were detected with mouse anti-V5 monoclonal antibody (Life Technologies). The Golgi marker GOLPH4 was detected with rabbit anti-GOLPH4 polyclonal antibody (Abcam). The processed cells were mounted in ProLong Gold antifade mounting medium (Life Technologies), and the images were acquired with an LSM880 confocal microscope (Carl Zeiss). Images were analyzed using ImageJ software (Fiji).

**[2-3H]Mannose Labeling Experiments for Lysosomal Enzymes**
Labeling experiments were performed with transfected GNPTAB−/− HeLa cells as follows: 48 hr post-transfection, cells in 60 mm tissue culture plates were incubated with 50–150 μCi of [2-3H]mannose (Perkin Elmer) for 2 hr, followed by the addition of complete medium containing 5 mM glucose, 5 mM mannose, and 10 mM NH₄Cl to stop mannose uptake and induce secretion. The cells were incubated for an additional 3 hr before the medium was collected for analysis. Acid hydrolases secreted into the media were immunoprecipitated, and oligosaccharides isolated and analyzed essentially as described in detail previously.20 Because the LAMAN, GAA, and GBA cDNAs contained a C-terminal myc-tag, 20 μL anti-myc monoclonal antibody (Santa Cruz Biotechnology) was pre-bound to 100 μL Protein G-agaroase-PLUS beads (Santa Cruz Biotechnology) prior to immunoprecipitation of these lysosomal hydrolases from the media. In the case of GLA, the secreted enzyme was immunoprecipitated with Protein G-agaroase-PLUS beads pre-bound to anti-α-Gal antibody (Amicus Therapeutics). Immunoprecipitated material was treated with Endo H (NEB) and filtered with Ultracel-10K (EMD Millipore). The filtrate containing the released neutral and phosphorylated high mannose glycans was treated with mild acid to remove any N-acetylglucosamine residues still attached to the phosphate moieties and applied to a QAE-column matrix to separate the oligosaccharides bearing zero, one or two Man-6-P residues. The retentate containing Endo H-resistant complex oligosaccharides was treated with Pronase (Roche Diagnostics) and fractionated on ConA-Sepharose 4B (GE Healthcare). The [2-3H]-mannose content of the various fractions was determined, and the percentage phosphorylation was calculated as described.20

**[2-3H]Mannose Labeling Experiments for Total Soluble Glycoproteins**
Labeling experiments were performed with transfected GNPTAB−/− HeLa cells as follows: 48 hr post-transfection, cells in six-well plates were incubated with 10 μCi of [2-3H]mannose (Perkin Elmer) for 2 hr. Following the 2 hr pulse, cells were rinsed twice with PBS and harvested, then resuspended in detergent-free buffer containing 25 mM Tris-Cl (pH 7.2) and 150 mM NaCl at 4°C with a protease inhibitor cocktail (Life Technologies). Cell were lysed by sonication, then subjected to ultracentrifugation at 100,000 × g for 1 hr to separate the membrane proteins from the soluble fraction. One hundred microliters of the soluble fraction was then incubated with purified CI-MPR that was covalently conjugated to Cyanogen bromide-activated-Sepharose 4B in order to pellet the mannose-phosphorylated glycoproteins, while 10 μL of the soluble fraction was precipitated with 1.5% phosphotungstic acid to obtain total [2-3H]mannose label incorporation into the soluble proteins. This method allowed the accurate quantification of all the mannose-labeled glycoproteins that were phosphorylated by either WT or mutant GlcNAc-1-PT.

**Enzyme Production**
Mouse D9 L-Cells were co-transfected with GAA cDNA, along with empty vector, WT α/β precursor, or S1-S3 mutant. Expi293 cells were co-transfected with LAMAN, GBA, or GLA cDNAs, along with either empty vector, WT α/β precursor, or S1-S3 mutant. The media was harvested after 2–3 days. For the production of GBA, 10 μM of compound AT3375 (Amicus Therapeutics) was added to the media to stabilize the secreted enzyme.

**CI-MPR Affinity Chromatography and Lysosomal Enzyme Assays**
Soluble bovine CI-MPR was purified from FBS and covalently conjugated to Cyanogen bromide-activated-Sepharose 4B (Sigma-Aldrich) as described.21 Aliquots of media from 2- to 3-day transfected Expi293 cells or mouse D9 L-cells were diluted with buffer A (25 mM Tris-Cl [pH 7.2], 150 mM NaCl, and 1% Triton X-100) and incubated with the CI-MPR beads at 4°C for 1 hr to bind the phosphorylated lysosomal enzymes. The beads were then sedimented, washed with buffer A, and assayed for lysosomal enzyme activity as described.12,22,23 The amount of the starting enzyme recovered on the beads was calculated.

**Cell Uptake of Lysosomal Enzymes**
Parental HeLa cells were plated on a 12-well plate at approximately 80% density 1 day prior to the cell uptake experiment. Aliquots of media containing each enzyme from the producing cells were added to the parental HeLa cells in a final volume of 500 μL. For competition...
experiments, Man-6-P was added to a final concentration of 5 mM. The cells were incubated with the media for 24 hr, and then the cells and media were collected separately. Cells were rinsed twice with PBS and then lysed in buffer A. The media and cell extracts were centrifuged at 20,000 × g, and the supernatants were assayed for their content of lysosomal enzyme activity.

SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found with this article online at http://dx.doi.org/10.1016/j.omtm.2017.03.006.

AUTHOR CONTRIBUTIONS
L.L., W.-S.L., B.D., and S.K. designed experiments. L.L. and W.-S.L. carried out experiments. L.L., W.-S.L., B.D., and S.K. analyzed data. B.D. and S.K. drafted the manuscript, and all authors contributed to editing it to produce the final version.

CONFLICTS OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGMENTS
This work was supported by National Institutes of Health grant CA-008759 and the Yash Gandhi Foundation.

REFERENCES